Click on a filter below to refine your search. Remove a filter to broaden your search.
Nearly 400 million doses of vaccine made by Emergent had to be destroyed “due to poor quality control.”
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
Evidence from a phase 2 trial suggests positive effects on cognition and gait in elderly patients with type 2 diabetes.
Sanofi is the third company to cut prices on its insulin products and cap out-of-pocket charges to $35 a month.
Although there was a slight drop in potency against the Delta variant, the vaccine was more effective against the Delta variant than the Beta variant.
The device would be surgically implanted into patients’ brains, with the idea that it would connect with computers to decode brain activity.
No benefit was seen for episodic memory or executive function at six or 18 months for older adults, but cognitive performance didn’t decline either.
In laboratory studies, two doses of the vaccine stimulated the production of more neutralizing antibodies than an approved mRNA vaccine.
The trial results could be out by September and may lead to the FDA emergency use authorization.
The shortage is expected to last until at least June 30, according to the American Hospital Association.